VA Marks Benefits Milestone For Veterans
The Health and Benefits app, which has 1.4 million active users, provides veterans access to information on health care and benefits.
It allows users to refill and track VA prescriptions, review appointments, review claims and appeals status, submit evidence for claims and appeals, review VA payment and direct deposit information, locate the closest VA facilities, access the Veterans Crisis Line and show proof of Veteran status.
VA Acting Assistant Secretary for Information and Technology and Acting Chief Information Officer Eddie Pool said: "VA's Health and Benefits app gives Veterans fast and convenient access to a host of important information, from appointments to prescriptions and benefits. We encourage all VA-enrolled Veterans to stay connected and informed by downloading the app."
This story will be updated.
Related Articles
How Veteran's Benefits Are Impacted by Trump's Tax Bill: What to KnowHegseth Joins Veterans in Normandy to Mark 81st Anniversary of D-DayList of Cities Hosting 50501 Protests on June 6Harvey Milk Navy Ship To Be Renamed-Vets Call It 'Insult to LGBTQ Troops'
2025 NEWSWEEK DIGITAL LLC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Trade-offs abound as big pharma makes direct-to-consumer transition
Novo Nordisk is the latest drugmaker to slash the price of a blockbuster medicine via its online platform amid drug pricing reforms in the US, but analysis shows a smooth transition to direct-to-consumer (DTC) channels will be tricky. US President Donald Trump has made reducing drug prices in the country one of his administration's key targets. He has spearheaded this goal with the Most Favoured Nation (MFN) policy, a legislative framework that would tie US drug prices to the lowest prices in other developed countries. As part of this push, Trump has urged pharmaceutical companies to embrace DTC business models. This includes companies establishing their own platforms or opting in to those from third parties that cut out middlemen, meaning final drug prices are lower. GlobalData's senior pharma strategic intelligence analyst Wafaa Hassan comments: 'The [DTC] development, closely tied to the administration's 'America First' healthcare agenda and its revived MFN pricing framework, marks a renewed phase of pressure on drugmakers to lower domestic prices while signalling alignment between the White House and the pharmaceutical industry.' Earlier this year, Novo Nordisk unveiled its DTC platform NovoCare Pharmacy with a heavily discounted price for weight loss drug Wegovy (semaglutide). Just this week, the drugmaker added type 2 diabetes treatment Ozempic (semaglutide) to the platform. Both drugs are available to cash-paying patients for $499 each for a monthly supply. The list price of both drugs in the US sits at around $1,300 per month. While the move to discount the two drugs is more likely a response to the popularity of cheaper compounded alternatives, Trump will nevertheless be pleased with Novo's decision. Ozempic – a drug that generated global sales of $10bn in Q2 this year alone – being available for cheaper on a DTC platform is a coup Trump will likely point to in the face of criticism for his pricing reforms. However, challenges such as a limited patient awareness and disruption to traditional distribution channels could hinder the adoption of the DTC models by pharma companies, according to analysis by GlobalData. Hassan adds: 'From a drugmaker perspective, more challenges will occur following the initiatives, such as new operational demands, margin pressure and potential friction with insurers. The likelihood of success will only depend on how well the pharma industry navigates these trade-offs in the upcoming months.' Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo's main rival in the GLP-1RA arena, Eli Lilly, has also conducted similar moves. The company began offering its weight loss medication Zepbound (tirzepatide) to self-paying patients at a steep discount on its own DTC platform LillyDirect in 2024. Taking a page from the two GLP-1RA developers, Bristol Myers Squibb (BMS) and Pfizer also established a DTC online programme for their blockbuster blood thinner Eliquis (apixaban) in July. BMS, Pfizer, Eli Lilly, and Novo Nordisk were among 17 pharma companies to receive a letter from Trump requesting more steps be taken by them to cut drug prices. "Trade-offs abound as big pharma makes direct-to-consumer transition" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
4 hours ago
- Newsweek
Medicaid Implementing Major Change
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Trump administration's Centers for Medicare & Medicaid Services (CMS) has rolled out a new initiative requiring states to conduct monthly checks on Medicaid and CHIP (Children's Health Insurance Program) enrollees, according to a new report by Fox News' Alec Schemmel. The change would affect those whose citizenship or immigration status cannot be confirmed through federal databases like the Social Security Administration and DHS's SAVE program. According to CMS, the first round of individual reports went out Tuesday to all 50 states and D.C., with states expected to verify status and report back. "We are tightening oversight of enrollment to safeguard taxpayer dollars and guarantee that these vital programs serve only those who are truly eligible under the law," HHS Secretary Robert F. Kennedy Jr. told Fox News. CMS Administrator Dr. Mehmet Oz added that "every dollar misspent is a dollar taken away from an eligible, vulnerable individual in need." This is a breaking news story. Updates to follow.
Yahoo
6 hours ago
- Yahoo
Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?
Diabetes patients in the US will now be able to purchase Ozempic for half its usual cost. Novo Nordisk, a Danish pharmaceutical company, said on Monday that it would be providing the drug through its direct pharmacy service for $499 (£369) per month, instead of just under $1,000 per month. The drug giant said it had made a deal with healthcare firm GoodRx to make Wegovy, its obesity drug, available at this price in over 70,000 pharmacies nationwide. It comes after Novo Nordisk saw sales plummet last month, after competition ramped up in the US. The company said the profit warning came as a result of 'persistent use' of compounded – or copycat – versions of its drugs, as well as 'slower-than-expected market expansion and competition'. It has faced serious competition from Mounjaro, Eli Lilly's rival weight loss jab, as well as what it described as 'unsafe and unlawful mass compounding' in the market as weight loss and diabetes drugs have soared in popularity. Ozempic and Wegovy both contain glucagon-like peptide-1 (GLP-1). It works by stimulating insulin secretion, which is why it helps patients with type 2 diabetes, but it also signals fullness to the brain. Wegovy only triggers the GLP-1 receptor in the brian but Mounjaro works on both GLP-1 and GIP receptors, which can lead to more weight loss. In March, Novo Nordisk reduced the cost of Wegovy for cash-paying patients, but now people without health insurance will be able to purchase it for this price. Trump's critique The move comes just weeks after President Donald Trump criticised GLP-1 agonists for being more expensive in the US than in other countries, adding that he would 'slash the cost of prescription drugs' by 80 per cent. Last month, Trump wrote to pharmaceutical leaders demanding that they 'negotiate harder with foreign freeloading nations'. He said: 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He's since upped that number, saying he would cut drug prices up to '1,500 percent,' which is mathematically impossible without entering negative numbers. He also said that European nations were 'unfairly shifting the cost burden onto American patients' by using their healthcare services to put pressure on US pharma companies to accept lower prices. Novo Nordisk said that the price cut was unrelated to discussions with the US government. Pfizer CEO Albert Boula has said he and other pharma companies are in talks about making their drugs available at a lower cost. Will it impact the UK cost? In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump. In a statement, it said it would continue to focus 'on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most'. However, last week, weight-loss drugmaker Eli Lilly said it would increase UK prices by as much as 170pc due to concerns about unfair pricing. The company said obesity drug Mounjaro would rise in price from Sept 1 in order to address 'pricing inconsistencies compared to other developed countries, including in Europe'. The company's weight-loss jab will cost between £133 and £330 per injection (depending on dosage) in the UK. CheqUp, a weight-loss jab provider, reported that sales of Wegovy increased more than 500pc, following the Eli Lilly announcement.
